Peptide Dosage Charts

5-Amino-1MQ is an orally bioavailable NNMT inhibitor studied for adipose tissue modulation and NAD+ preservation. Typically formulated as 50mg or 150mg capsules.

Cagrilintide is a long-acting amylin analogue researched as a standalone satiety modulator and as a partner to Semaglutide (CagriSema). Once-weekly subcutaneous administration.

FOXO4-DRI (FOXO4-D-Retro-Inverso) is a research senolytic peptide studied for selective clearance of senescent cells via disruption of the FOXO4-p53 interaction.

GHK-Cu is a naturally-occurring copper tripeptide studied extensively for skin remodeling, wound repair, and fibroblast activity. Researched via injectable, topical, and intranasal delivery.

GLOW is a researcher-popular blended protocol combining GHK-Cu, BPC-157, and TB-500 into a single subcutaneous injection studied for skin quality, connective tissue recovery, and inflammatory modulation.

MK-677 (Ibutamoren) is an orally-active ghrelin receptor agonist studied as a growth hormone secretagogue. Supports once-daily protocols due to its ~24h half-life.

MOTS-c is a mitochondrial-derived 16-amino-acid peptide studied for metabolic regulation, insulin sensitivity, and mitochondrial resilience.

Selank is a synthetic analogue of tuftsin developed as a nootropic and anxiolytic research peptide, most commonly administered via intranasal spray.

Semaglutide is a long-acting GLP-1 receptor agonist extensively studied for glycemic control and body composition. Once-weekly subcutaneous administration is standard.

Sermorelin is a truncated GHRH analog (GRF 1-29) studied as a GH secretagogue. Short half-life makes evening subcutaneous dosing the typical research pattern.

Tesamorelin is a stabilized GHRH analog with a trans-3-hexenoyl modification that extends plasma half-life relative to Sermorelin. Studied for visceral adiposity and GH axis support.

Retatrutide is a once-weekly triple agonist targeting GLP-1, GIP, and glucagon receptors. The Jastreboff Phase 2 trial (NEJM 2023) reported up to 24.2% mean body-weight reduction at 48 weeks with the 12mg dose, and Lilly's TRIUMPH-4 Phase 3 readout (Dec 11, 2025) confirmed 12mg as the lead dose.

BPC-157 (Body Protection Compound) is a 15-amino-acid pentadecapeptide derived from a sequence in human gastric juice protein. Studied extensively in rodent models for soft-tissue, tendon, and gut-barrier repair (Sikiric et al.). No human randomized controlled trials have been published as of April 2026.

The CJC-1295 (no DAC) + Ipamorelin pairing is the canonical research GH stack: a short-acting GHRH analog combined with a selective ghrelin receptor agonist. CJC-1295 (no DAC) PK was characterized in Teichman et al. 2006 (PMID 16352683). Ipamorelin's selective GH-releasing profile was established in Raun et al. 1998 (PMID 9849822).

PT-141 (bremelanotide) is a melanocortin receptor agonist (primarily MC4R) studied for hypoactive sexual desire disorder. The FDA-approved formulation, Vyleesi, is a 1.75mg subcutaneous autoinjector dosed on demand, supported by the RECONNECT trials (Kingsberg, Clayton et al., Obstetrics & Gynecology 2019, PMID 31033583).

Tirzepatide is a dual GIP and GLP-1 receptor agonist marketed as Mounjaro (type 2 diabetes) and Zepbound (chronic weight management). The SURMOUNT-1 trial (Jastreboff et al., NEJM 2022, PMID 35658024) reported mean body-weight reductions of 15.0%, 19.5%, and 20.9% at 5mg, 10mg, and 15mg over 72 weeks.